Neurokine Pharmaceuticals Inc.

OTC Bulletin Board : NEUKF


Neurokine Pharmaceuticals Inc.

June 01, 2010 17:33 ET

Neurokine Announces Changes to Management and Private Placement

VANCOUVER, BRITISH COLUMBIA--(Marketwire - June 1, 2010) - Neurokine Pharmaceuticals Inc. (OTCBB:NEUKF) is pleased to announce changes to its management. 

Ms. Penny Green has resigned as officer and director of the company, effective immediately. Ms. Green played a key role in restructuring the company for its public listing. To replace Ms. Green, the company has re-appointed Dr. Hassan Salari, one of the founders of Neurokine, as a member of the company's board of directors as well as its Secretary. 

The company is also pleased to announce the appointment of Mr. Judson Cutler as the company's Chief Financial Officer, accepting the resignation of Dr. Doroudian from this same post. Dr. Doroudian remains the company's Chief Executive Officer, President and a member of its board of directors. 

In conjunction with the appointment of Dr. Salari, the company closed a private placement of $20,000 USD at a price of $0.005 per share by a company controlled by Dr. Salari.

About Neurokine

Neurokine Pharmaceuticals Inc. focuses on development of new use for existing marketed products for diseases mediated by acute and chronic inflammatory reactions. The company is developing proprietary encapsulation technology to allow better blood brain barrier penetration to initiate or enhance therapeutic effects of anti-inflammatory drugs in the treatment of neurodegenerative diseases.

Disclaimer

Except for historical information contained herein, the matters set forth above may be forward-looking statements that involve certain risks and uncertainties that could cause actual results to differ from those in the forward-looking statements. Words such as "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Neurokine or its management, identify forward-looking statements. Such forward-looking statements are based on the current beliefs of management, as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors such as the level of business and consumer spending, the status of Neurokine's products, the competitive environment within the industry, the ability of Neurokine to expand its operations, economic conditions in the industry and Neurokine's financial strength. Neurokine does not undertake any obligation to update such forward-looking statements. Investors are also directed to consider all other risks and uncertainties.

Contact Information

  • Neurokine Pharmaceuticals Inc.
    Ahmad Doroudian, Ph.D.
    President and CEO
    (604) 805-7783